DCTH - Earnings call transcript Q2 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to Delcath Systems' Second Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Mr. David Hoffman, Delcath General Counsel. Thank you. Mr. begin. may you Hoffman,

David Hoffman

Pennell, once Chief and to the the me harbor Business Gerard Chief Interventional like Officer; pursuant call And the Kevin XXXX. Officer. I'd of historical Litigation Quarter call, the General XXXX Operating Officer; of safe of made Muir, on made Systems forward-looking is statements described by in and XXXX call XXE safe are Securities exception Manager, Section for facts, Sandra Executive Chief Earnings Highlights Vojislav and Michel, begin Vice this statement Private statements considered again, you. XXA forward-looking reading President the of Reform within Delcath Finance; This Vukovic, welcome Oncology; Second the statement. Securities of Senior Exchange Medical Thank to to Call. Rook, be With with Securities of Act the on All the Act harbor may Section XXXX. the meaning of Act statements of Martha

the that forward-looking those various assumptions are differ no and Actual from believes may makes in implied prove or it reasonable, these to forward-looking assurance statements results Although expectations expectations have reflected been that materially to statements correct. will due expressed in such and risks company uncertainties.

Securities on filed company Commission. reports that time the with to such report the annual Exchange statements, from company's forward-looking please For XX-Q, could Form reports cause factors uncertainties implied in in other and XX-K, those in contained of as as and the a actual discussion from those which in subsequently the see well Form quarterly risks files on or time results to expressed differ detailed risk

or as date in events any We are supplement or knowledge, made this of update circumstances. forward-looking any undertake Any forward-looking call. this obligation to statements subsequent call to statements reflect the included do not of only

additional details with under Investors results. about on available includes release section, our our XXXX quarter our the press website, www.delcath.com, and financial Our second results is

also today's has latest filings, our our which recording you SEC will of we available call website on encourage A Our be to review. website.

the Michel. like Now turn I to over please would Gerard, to proceed. call Gerard

Gerard Michel

for everyone, you, joining. Thank

During second treatment of including for quarter ongoing site Delcath's as for activities, activation our rates as commercial projections updates. today's average and well the medical both the will call, financial and some year, we review results, clinical balance important

revenue the second million including total in in and reported revenue HEPZATO Delcath million from European $X.X $X.X In for quarter, U.S. $X.X million revenue, CHEMOSAT. in

number and previously key ramp our the activated, we average treatments described, centers per per the -- number average once the of drivers of revenue center are in As treatment activation, have U.S. center. of

of coming the level, very, From our ramp, overall quarters very thrilled in we're terms a high encouraged with we will our progress about bring. are and what

with the quarter X Now we of sites. specific, have today, site as sites. activation, terms be ended second of to active we active And X in

While is we call, our previously X of this fell just center ahead per projected projected rate. well communicated per last under our in of rate the month below just the number treatment

dig activation. and first deeper to metrics like both to little a into turn I'd center

anticipated, than centers of the haven't is to of we activating complexity for the stakeholders number for halt process. but the increase time seen given just some important at process the It's the in there of it's in slower that function any bit activation, note a a systemic a been instead has simply activation no activation center While reason involved. center center

XX centers, currently all our stands centers HonorHealth University are at One centers North Scottsdale. University University, University Center, Hospital Cancer University Tennessee, Carolina Cancer the conversations Wisconsin, we confident of sites, will of Center, X XXXX. or over Health which centers active From of Thomas are our Cancer Moffitt with ongoing be include the of The process, beyond and in that the active active today that in active Regional Center, UCLA Jefferson Stanford

Two each additional month. scheduled have first their the treatment preceptorships this having centers completed required and all

August centers. first should process X commercial currently proctor the treatment guidance are cancellations, treatment proper identifying Assuming under we of patient the their HEPZATO the no An steps of scheduling necessary KIT. with end completed a XX conduct a for additional in treatment and with to have the and centers

I've the As proctors to fit algorithm complex that patients' past, in all mentioned needs that a as the can as the as with given arrive need scheduling well well. be that

requirements. XX a and with completing institutions portion anesthesiologists date, U.S., XXX further centers preceptorships, some had multiple representing X radiologists the A institutions preceptorship sending care health in over have we To of are perfusionists, currently the interventional over attend providers.

XX We are X successfully the are next activate in months. within of that confident will the centers currently the process that activating

greater per I'd date of center Now activation, we the into higher during treatments month which little second per been average center by under a the call. a just metric, has projected in vast of will last to the centers commitment like a notably center, dig given than average Adjusting surprisingly, volumes meaningful X our than revenue either for believe Not active was treatment majority the currently become treating the quarter. have the that centers activation active become But to contributors. we second some process center, treatment required REMS-certified others. undergoing or

present X with with the sites, active started X sites We today. third quarter active

we quarter anticipate mentioned with before, end we third can XX the active sites. As I

centers in shortly early quarter anticipate the the by reach XXXX and XX thereafter. XX having to of expect end We or fourth

part group our a average, some before what quarter treatments patients. center balance active X HEPZATO somewhat While centers, just year, where for month under between for in under in we the average a pattern month are call. per we the averaged initial when for center above treating the then more seeing patients This estimate treating adjusted in to last treatments for will on we additional treat or treating but of projected is centers treatments patients, an treatments the second quarter started second and X per based pause the of X.X

of the patient of Besides our payers flow opportunity steady outcomes, benefits an a for before approving provides pause assessing patients. to the from centers explanation evaluate

therapies many of hospitals, benefit within which dynamic code, you J a this for such a risk in ours procedures of the product-specific As situations greatly of the new even of common has know, rollout where reduces and premium the product is underpayment. as innovative

costs effective patients for payment XXXX. morning's Payment release CMS the Some seen of October for will may that we were we in that NTAP inpatient under which treatment additional X, the starting the by granted you stay. with on have we small press this Add-on cover help that Medicare percentage informed shared of designation August HEPZATO New X require Technology associated status might This for were

do J-code being outpatient as patients billed thus, basis, And up ASP for X%. reminder, to most is those Medicare patients not product inpatient. the a billed plus under at the end reimbursed hospital As in an

of the our by quarterly expect we quarter pace remaining the exercise revenue that cash fourth is XXXX. continue U.S. trigger from of warrants tranche year, achieve in -- part in expected March to we million as of were proceeds in Given we the million approximately to of revenue expect which ramp, that financing $XX this the of will $XX issued

presence and market will Europe submitting we the review a a process dedicated that the over the growth and prior over for year. reimbursement in understand of The result have from as XXX% period for commercial sales is We're of Germany over U.K., year. now in the majority in place same take having in CHEMOSAT that increased of year. next a the

the approximately While CHOPIN as all we are trial. treated melanoma Netherlands treated those uveal being in patients ongoing of estimate almost XX% of part with metastatic patients the all CHEMOSAT, being are

we We moment. have started Sweden, patients commercial at sponsoring CHEMOSAT, an ipi/nivo in looking which in a but detail IIT I greater in expect most sales sequencing are in enroll will with describe there to

the identifying chosen I've and measured centers it in investment manage in European basis. opening But the on and We are important Spain. mentioned market the before, major in point France, breakeven are believe have is in commercial Italy have and multiple we markets. low early our all as EU to treating We of given in a to price Europe being centers process

European in term and as sites, has in and a uveal These other have experience CHEMOSAT. adoption. publications, short melanoma types. can some tumor a of of medium that and our a the of Recall tumor solid U.S. is both worth activities device with broader trial value metastatic The over of pan support source EU Europe label to sites CHEMOSAT decade's both

significant growing delivered KIT, CHEMOSAT liver as to other the or the option the procedure, external and to HEPZATO In activity, liver-dominant body of for we to Delcath commercial utilizing with support whether internal melanoma the addition potentially that as well important melphalan cancers. uveal both patients dominant by to treatment an is add continue PHP evidence efforts

with patients from results III journal announced in Surgical HEPZATO Annals publication Phase the In unresectable melanoma in of key quarter, we FOCUS the metastatic of second Oncology. the the trial pivotal uveal of

FOCUS the and study from be published the results additional to coming presented expect months. We

clinically study in patients important of For ESMO in as at accepted example, conference an subgroups efficacy analysis FOCUS upcoming has poster September. a the presentation been in

to medical integration algorithms metastatic with treatment the HEPZATO discuss is different engaging treatment U.S., EU medical of options sequencing interest oncologists continue treatment in and available significant we in use also community uveal melanoma. into commercial roll to HEPZATO As are of There in in we out and settings. the to the U.S. in HEPZATO evaluate combination

following successful a Frontiers would in metastatic melanoma published to of I like with in point checkpoint CHEMOSAT to uveal recent tebentafusp. and on failure immune inhibitors example, an a patient As single-case on publication Oncology treatment

inhibitors, As treatments followed quarter. immune against ipi/nivo I control. CHEMOSAT control. will checkpoint in a CHEMOSAT, a mentioned enroll with being IIT IIT, CHOPIN, and evaluates evaluate the Sweden by ipi/nivo first and as therapy to moment CHEMOSAT of with start compare IIT This in IIT expecting ipi/nivo patients we're the with second sequence nivolumab first new this sequencing treatment, or the is and ago, a which as This ipilimumab

of solid patients therapy In on aware CHEMOSAT combination in immune HEPZATO body of evidence and medical interested discussions tumors. with chemotherapy based between are immunotherapy or are we in immune physicians very and possible with a synergies in and published that exploring oncologists,

the heard physicians of of study results. the waiting immunotherapy utilizing in CHEMOSAT combination CHOPIN We and multiple publication reports have without anecdotal sequence or for completion

the second XXXX. the in of study CHOPIN enrolled. that continues mid-XXXX, total XX with occur the analysis On planned to presentation of progress XX investigators patients the to endpoint primary in with of the of half anticipating results are final note, Currently,

the lines of survival endpoint definition the As by year. uncertain. for trial of events primary depends X so the CHOPIN data the collecting appropriate a on number is analysis are at somewhat This reminder, readout progression-free time

the continue breast development or cancer path. We colorectal months plan to boards advisory over to in CHEMOSAT on clinical and and focused scientific more initiate additional X indication the X next recently define HEPZATO conducted an to X better studies of

provide updates plan will our development on We clinical year. this later

position. financial our call I will the to share over some on hand Sandra Sandra? now to details

Sandra Pennell

of $X.X Thank sales Gerard. million, in million and CHEMOSAT the X during compared XXXX, for $X.X for Revenue same months you, CHEMOSAT period from XXXX. XX, our were were HEPZATO the million to June $X.X ended

XX% in Our gross the second margins quarter. were

For the increase XXXX. in XX, million The June product. in XXXX, X expenses personnel-related months due and in months primarily improved medical X an clinical expenses in affairs, costs $X.X ended expenses development million, June were regulatory development and to trial with for compared is decrease and the activities, to ended offset $X.X change an research associated research a XX, by

expenses commercial the For general the is the The launch, million due $X.X administrative for X additional and same marketing-related June to to activity to compared XX year million. team. selling, increased XXXX, commercial including increase period ended personnel $X.X on in from expenses and months this

million operations and resulting million with we company cash X, made. achieve likely We research quarterly resources exercise final proceeds. On fund million the should $XX current loan believe investments approximately until trigger and development and of quarter. cash flow until adequate ended would $X.X revenue, operations a in matured financial and $XX cash be sufficient This expenses. to U.S. in of become the with which warrant payment under that the current levels We was used company fund $XX in positive our to $XX.X Avenue in second the was in August million QX million are fully

As confident million year. achieve quarterly U.S. in revenues $XX previously mentioned, the will Gerard quarter of by we fourth we this remain

for That ask prepared please concludes remarks, Can for check to questions? and Q&A. the lines you our I'd the phone operator open

Operator

first Genuity. the The with Newman Instructions] John comes [Operator Canaccord question line of from

John Newman

XX treatments I quarter. a still comment but of bit seeing and you're in just terms launch, as to mean how that for could you say, curious of know on the what to Congratulations to in of on number HEPZATO, the XX progress early you months. expect over would next, the the it's trend kind

Gerard Michel

Sure.

this But getting X patients the are X, X, seems So in they'll too like we're in given to procedures. least are or progressing than match we'll no support well X, I we that indication specialists lower now reps from anecdotal it at was and best really to It's But this it's not on But say be most average. of clinical which saw what early on whether who most or it . the more. the that the do X.X over suspect point. trial, at at that time. will or

John Newman

in Okay. If Great. seems one additional of a potential like could I HEPZATO approval. beyond question. lot sneak additional for there's It the

beyond You CHOPIN. spoke a trials bit about additional

you trials that be expect of have maybe some would you would smaller studies sort controller? do that single-arm those curious, studies? also Just expect might those of Or

Gerard Michel

Yes.

mix do going we're to think a of things. I

And well think and arm, although likely trials. randomized as as through So would have now probably working single the with Voji arms, with some those right single as to advisory committees control well. investigator-initiated control studies those more of multicenter be larger is both

you'll a some at that trials would are us, So from randomized we mix look in have might that trials trials, things We of I some data. control ranging think from think arm. have see mind a sponsored historical and

of with single a example. control data, registry arm like a [indiscernible] for a sort So arm

expand things. And will adequate for from can way potential mix not it the an label. patients the goal The again, giving trying So data to judgment the to make they physicians for down treat certain as to of informed patients, be the well. get to so be whether reimbursed be the or will to all try will and a want ranging mix road, informing a goal, guidelines

So be it mix. will a

Operator

line comes BTIG. question from with the Next of Thibault Marie

Marie Thibault

on Is there If don't a highest Moffitt, to I per kind center for the way still average I out J it's I Thank Sandra, was this know group? course, with into bit last Gerard, about center, you on think things. And to the of Wanted just it going on to were the very smoothly quarter. everything detail. help mentioned check quarter, we are effect, front? dig quite supposed that know little nice remaining going metric. that they that average Is treatment was, code of a for giving that to to you and that a the pausing billing know volume strip if us quarter. bit.

Gerard Michel

Yes.

they when question second with of reimburse and paid. have back if and heard heard me right. couple of paid. cases things it go fundamental always get go they I to no takes fix they had wrong then with to a get things bit the done do which first. where Let of opportunity a have answer if I back, they But the they little longer. have And problem things the right, hospitals do don't, they've they've and

there that Everything all. So seen very been issue fundamental no I've at positive. has

Moffitts most -- if out breaking the the and treatment average will the average stripped from of to will Thomas more month, I least Jeffersons, up. giving Moffitt yes, bringing a of level. do the dropped. that hesitate eventually say be will Jefferson than terms and going many In the I it rates, you X are I'm treatment think to down that. at and per Thomas week do averages centers But clearly

hit the as start wait couple not gas. addition, centers seem them, and to and all but patients In to many new of a of on, do then of them come

downward I So but on will kind centers those keep average average, maturing flat. -- drive, the of new centers pressure think, the really the average will the

balance X why year. X.X that's it to be will the think I somewhere for the net-net, of So between

Marie Thibault

helpful. really That's Okay.

there to so any you up sustainability some gross good quarter, For you launch is reps wanted were needing Just us here, both how that. Help about of I the OpEx a of your think good margins sales there. and the keep Are operating on plans? more of with add follow-up kind to control. Was reason more side? give the this us margins can a control detail underscore your to spend

Gerard Michel

Sure.

think the to who the [indiscernible] force of sales a wisely. kind spend be side. here come have going from product another a all players I similar specialty that huge A reach disciplined OpEx we're need This to fairly is don't is lot centers. We company of know, the on money centers.

maybe the about I past, to talked XX think I to getting in XX.

decide on like Our to that might get evolving increase We or a SG&A not thinking relative might more there. are a XX, where to huge increase. is marginal we XX have to now, but

to believe. of In cost do any CapEx, of terms X, of for goods, tie-up we before great have I X years meaningful we're

So there. we're shape good in

So But doubt biggest I invest increase And be be really didn't we It indications. we're might to thoughtful be other just we decide about if for that to at into think is trials. we'd question, R&D that. this spend. the product very do will a is some preempting potential going want much we because -- R&D variable How has many we there's I point remiss -- R&D.? tremendous additional larger no be some would in much and

I'm going prudent. going now. and to But and going E EPS, an I to of forecast excuse try years in in say, that's to me, kind be shares. mean we I'll that's X.X of we're terms And be out to what from not of look, number there's understand -- very EPS, just an

raise the prudent going much money try very keep forward. to to more don't so we're to really cost be have going So down, to

Operator

Next with the Ramakanth H.C. question comes Swayampakula Wainwright. from line of

Swayampakula Ramakanth

that activations learnings the now it? there's not the And educate on smooth? activated of but preceptors this have or the XX of internally, so only Regarding from the if that pull is almost or next centers how end go you the the X what month, activations, center -- also helping are you that by set push any

Gerard Michel

parallel of committee some educate project from to think any various to really help there's try aside address of kind of and learnings the we need ahead stakeholders I in approvals stuff. the in don't get kind stakeholders the hospitals, and Yes. of dramatic

Rubik's stuff is of The a scheduling. preceptorship just training cube really

further scheduling. have As Kevin, of site people anything I like who terms that. can and easier. in now, do it in preceptorships, chime don't we available difficulty preceptorship it's But in right any you a along activation, we and learnings bit will know to about get get more proctors if want just or

Kevin Muir

the we it Gerard, procedures Rubik's to preceptorships Thanks, sites like more the for proctorships. the should have it increases I it scheduling. or have, the lessens opportunities the And increases, analogy, and I that say, Sure. the cube that and we Gerard. active of more --

So make easier. in activation that cycle respect, it account a should bit the

thing other The or of with it the now, allows to happen organically that scenes. conversations X we're working centers behind that XX kind for right peer-to-peer

So things do manner and up. set each physicians for reimbursement call checking how understanding on some to other hospitals and of

the So the when this as year. help go forward us of net-net second should in of will the centers that, streamline these activation half are -- is of kind process and all of the we

Swayampakula Ramakanth

Regarding received center? benefit number of way the of HEPZATO that NTAP KIT help of procedures in in this And the just of per that increasing any month, that earlier would in how you terms number received, that terms does adoption?

Gerard Michel

I in think getting don't make Yes. difference NTAP is uptake. of a to much of terms going

on into loss level think because it's I the certain to the of rather is percentage, critical. to certain I don't don't It's going it for I a certain will covers infrequent the then detail have that financial think burden inpatients. They percentage, hospitals It formulary. have think amount, that a have the complex a helpful lessen it they hospital. when worth which a up

how technology it's I People sign thing of thing or the think this a therapy bar get is. add-on payment pretty device, look of et -- more telling the is high. the But melphalan, at most a it's is new to it's truly cetera. innovative important

seeing and something the does it. they're got think the reaction I using and prove unrelated, you're we're to that out I innovative are think, else And seems that rate, they're there. therapy product, need do really although oncologists fantastic who it's an response the You from getting is that incredibly nothing doing the we positive. And radiologists it physician

It difference -- is shows truly that's We not why for of modest a filter, the that something patients. new And [indiscernible] is it's making It is think a it's again, that's chemo. So that got a I don't it. big we real need it's tailwind, deal. just NTAP. it a but this

Swayampakula Ramakanth

me. for question last One

for of going reimbursement On the since that than are is the if the correctly, comes to play time? U.K. how into time that used U.K. couple longer a I others, a there review from hospitals, when reimbursement, have it chemostat remember

Gerard Michel

the They doubt review went a pushed Yes, into what was recent change next a reimbursement, The I That semiannual have that. in what to from That's was do annual we'll surprise it an we're no back they year. about no get going to how review. just is, will get reimbursement. a question us. That doubt have the often be? review. to I But reimbursement

clinical high a mentioned I hopes now. a to going to be think it's breakeven where basis. to very, measured from we're -- But invest publications, it because source are the kind up don't we're and we before, it's sites right going in I will on important company. step asset that roughly again, basis very strategic on as significant a have generate of But for as continue to there Europe manage a a I

Operator

Loganathan the Sudan question from Stephens, Inc. comes Next line with of

Sudan Loganathan

first cash is endeavors? main the least quarter. have towards achieve and new positive, hospitals breakeven to potential clinical I Is to at what focus might next you on a then positive to quarterly this My a that towards congrats yearly anticipate understand strategy? And secondly, great goal on year any aspirations you strategy. a to indications the EPS? there getting more team, kit that, need as revenue selling do range one I to trying to also the for in have a is and and then Sandra you flow track regarding bring X rate into towards to questions. And or Delcath changes will achieve focus on more go breakeven at in patient awareness? sites, other to or the Gerard, prior HEPZATO, run marketing them geared launch, be marketing you or but OpEx or taking additional to physician and progress be the

Gerard Michel

Sure.

be why think, we you spend? at you Sandra, basis, current under on hit okay, to think to breakeven, don't I need a pick quarterly where up R&D

Sandra Pennell

to obviously SG&A, probably just I of flow dependent R&D quarter additional kits, XX cash spend around be this in of we're XXXX. Currently, depending, positive, flow rest be the course or Yes. year. marketing on breakeven XX well a the cash by think QX that hopefully, and and to incurred positive, the of But order on becoming will

Gerard Michel

And that's about $XX million a quarter in revenue.

Sandra Pennell

Yes.

Gerard Michel

All right.

all Now in I in I right switch to get site we're trying over to terms of XX% chime market, will the you disagree, if FOCUS FOCUS mean activation, But now, the time. moment. probably That that think, is couple years. Kevin, patients at sites. the XX% mix our don't if you about next want I might evolve over year, elements of important a are the now priorities sentences of to know maybe give how marketing and Kevin, the X.X

Kevin Muir

now, right sites the Sure. of And our while awareness through have is patients. we not population is a what these opening think it's goals access and drive main we that that think wonderful is option for patient patient with And our main one goal. to increase important, I is XX% to

as Our as open to many we not can. main is sites goal

XX Gerard with probably we've goal goal As ultimate out his a and around roughly in of with pointed of remarks, our started sites. XX

So and sites. sites? access those sites. patients our focus, it's the And patients to right correct at going we sites these the that's getting opening to giving sites? the been quality Are more Are access we of

Operator

the from of Capital Chase line comes question with Next Instructions] [Operator Group. Knickerbocker Craig-Hallum

Chase Knickerbocker

are of of other a those that Thomas early being me, quarter per there the in from from after generally like a of of per Jefferson? of pause maybe pipeline here average that kits think the first down and everyone so kind else over as high-end couple Just adopters bit we or center active? Or Moffitt first number of any should kind drag month patients or kind them

Gerard Michel

that think be third surprise it but to center And there's recent there'll will And kind that that of I level become think at the wouldn't our have some that opening they're approach activity. us book a lot increasingly some given say of they treatment, destination number were I I level. of business, of might terms a at think a reach that of they a I that centers of that level, others once patients. weren't will for a in

think Will So But don't will -- month, I up up we X I few centers week we're ton maybe having a quite more and eventually. end we quite centers -- X? or a that that a X I a me. quite excuse think centers having going Yes, think of mean, few I end a week. X doing so, X have a than don't to doing are being

that mentioned. therapy, you up aren't them start going treating will if in. lot Pareto So the I you guys our analysis look at appropriate our big of But once end to the those if the patients maybe bringing for kind think therapy, at who look you but centers, -- of centers, are they're a have of they

becoming they'll So start destinations.

Chase Knickerbocker

a of Should what any think that the kind high on of we of adopters is of of those to could the that level think for mean high end? us of kind constraint max some about per kind kind week of I treatments do? way

centers numbers up, we of the yourselves. scheduling, the a for awaiting so I'm line a a treatment that schedules were gave making of just general example, repeat do takes? how I kind But kind kind kind to activate of to of get X, forgive second, the we that of do feel then that initial me you just have are kind for kind of And those of we that if patients? long commercial long awaiting on lot call, kind of know a of it of sense those how takes

Gerard Michel

And off X all weeks, about we're can projections. X X now cetera. I by map. should the the in had the over -- a we thought over weeks, end patient have doesn't last all -- the all been X. call, We is nobody show at proctors It it's didn't. or And of up, we and No, be be then a why my it X was et or should at X, really of get in we'd that's we quarter, XX a map. If [indiscernible]. I

you And kind Europe In if think to we centers what terms high-volume do pretty on centers, had it be we've of in of week. for that, we had have not. a a natural run couple it's X believe recently although max is a -- X regularly or in of summer what a vacation, X rate, or seems of were doing center that not day, rate

X a So that up may center a X-a-month being end month, type place.

are used to have or high to now, X be does doing to X I team end or of for they think people a this be or will a So backup month. or a end as train right a the X others months bit month. are going a likely second willing and X up might I what get But think X people, couple

think I regularly eventually of the it we did day. to a time. week. But bit -- that X they X just some a I do X that last a ago, week, other weeks and that sites -- center we'll X X again, take will think see did And saw

So they were able to push them through.

Chase Knickerbocker

then for And color. helpful me. That's last it. just Got

kind you're look kind then -- community about patients therapy those are who those this patients some are is referrals Just And progress an the for early me give are eligible physicians in-line your centers. getting of kind Or little to speak of of having eligible it's to is something it viewing know a of the tebentafusp that where bit first? tebentafusp. kind kind going there. treatment? that Just driving early, look with of maybe -- early that of are Are but these those I how to interact an maybe at in with

Gerard Michel

before therapy that whether liver and go to really patients after believes we've with these do has had succumb what tebe And the We've it tebe. had first liver because patients are doc this more patients directed usually should to. mets

they're if to going prioritize to therapy. some liver-directed want So docs treatment, prioritize

and another. But long one therapy. it than or all So the most of patients will more it's out over X over settle way enough line to live time probably do map, get

the probably HLAX tebe right go I positive they thing first for who or patients both. patients. get the should whether on So It's on us, think are first

Voji's referrals. are In Kevin's usually setting Voji's terms it's don't working up team date. referrals referrals, We've are of team peer-to-peer know, commercial quite Kevin's had, and and both working referral a team few both -- to patterns. affairs team on early still medical I They're on days.

at a their So are we've their of to send patient up to to finishing they have. approval getting they have to that the patient knowing treated. the them They to -- going the need want referrals once to site, times, approvals been come They hopefully, finish waiting centers. various the them, centers of fall another from lot occur committees is have a or preceptorships back their

[indiscernible] So sites. we've also seen those peer-to-peer phone referrals. treating such in made And some due to directly sent we've we've calls patients

product. very become machine confident a now. terms patient referral In direct good excited going work will lot we're we something That's through evolve are of the that right do that of advocacy things about The increasingly well-oiled important. advocacy process, it. a groups It's We're developing can centers. to

this we'll with know where so So is work available. the them patients

We who's have these as to data treating reasonable patients.

know docs sense these X. in importance have who calls, patients N are cut of visits, them. of so equals just front KIT. we level Because X, has e-mails, about equals recognize we through try just get or of a N that. valuable, HEPZATO them, it to tell that each of we And of these to is the we to X them But developed to makes down X them, -- X of we of phone surprise process just X perhaps So where

developing that party programs with docs get who with it's of third in with get co-pays, process, the involved with. where probably We're work And there. also with Maybe reason we'll cetera. directly that that et numbers have travel, smaller has help patients. But us will a through to a touch referrals we patient help

So declare, early it's it's how to going well going of are a focused to that. we effort. Still working, to a say be multi-spoke be on kind days but

Chase Knickerbocker

Got it. here. on And early again congrats the progress great

Operator

This today's you. concludes Thank teleconference.

you Thank participation. disconnect for may time. You at lines your your this

Delcath Systems (DCTH) 5 Aug 242024 Q2 Earnings call transcript